EQ [NASD]
Equillium, Inc.
Index- P/E- EPS (ttm)-2.20 Insider Own0.10% Shs Outstand31.87M Perf Week10.62%
Market Cap86.70M Forward P/E- EPS next Y-1.33 Insider Trans-27.27% Shs Float18.87M Perf Month-18.57%
Income-67.50M PEG- EPS next Q-0.40 Inst Own41.10% Short Float4.39% Perf Quarter-31.88%
Sales- P/S- EPS this Y7.40% Inst Trans63.62% Short Ratio24.29 Perf Half Y-51.92%
Book/sh1.65 P/B1.52 EPS next Y10.90% ROA-76.70% Target Price13.17 Perf Year-60.51%
Cash/sh1.98 P/C1.26 EPS next 5Y- ROE-96.50% 52W Range2.12 - 7.75 Perf YTD-33.69%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-67.74% Beta1.25
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin- 52W Low17.92% ATR0.18
Employees45 Current Ratio5.50 Sales Q/Q- Oper. Margin- RSI (14)44.06 Volatility9.11% 7.72%
OptionableYes Debt/Eq0.20 EPS Q/Q-256.90% Profit Margin- Rel Volume0.54 Prev Close2.50
ShortableYes LT Debt/Eq0.14 EarningsMar 23 AMC Payout- Avg Volume34.11K Price2.50
Recom1.40 SMA20-0.18% SMA50-13.91% SMA200-44.77% Volume0 Change0.00%
Oct-29-21Resumed Stifel Buy $12
Sep-15-21Initiated Cantor Fitzgerald Overweight $14
Jul-14-20Reiterated H.C. Wainwright Buy $14 → $24
Jul-10-20Resumed Stifel Buy $22 → $10
Feb-22-19Initiated SVB Leerink Outperform $16
May-17-22 08:00AM  
May-12-22 04:01PM  
08:00AM  
May-09-22 08:00AM  
Apr-25-22 08:00AM  
Apr-04-22 08:00AM  
Mar-29-22 10:00AM  
Mar-28-22 12:00PM  
Mar-24-22 08:00AM  
Mar-23-22 04:01PM  
01:42PM  
Mar-04-22 08:00AM  
Mar-01-22 08:00AM  
Feb-16-22 11:22AM  
07:00AM  
Feb-15-22 08:00AM  
Feb-09-22 08:00AM  
Feb-02-22 06:46AM  
Jan-10-22 08:00AM  
Jan-05-22 08:00AM  
Jan-04-22 12:48PM  
11:39AM  
08:00AM  
Dec-13-21 08:00AM  
Nov-09-21 08:00AM  
Nov-05-21 08:00AM  
08:00AM  
Nov-04-21 09:00AM  
Nov-02-21 11:23AM  
08:00AM  
Oct-18-21 08:00AM  
Sep-30-21 08:00AM  
Sep-22-21 08:00AM  
Sep-08-21 08:00AM  
Aug-11-21 04:00PM  
Aug-10-21 04:01PM  
Aug-06-21 04:42AM  
Aug-05-21 08:00AM  
Jul-13-21 09:10AM  
Jul-12-21 04:01PM  
Jun-11-21 09:53AM  
07:00AM  
Jun-10-21 08:00AM  
Jun-09-21 08:00AM  
Jun-07-21 08:00AM  
Jun-03-21 08:00AM  
May-26-21 08:00AM  
May-17-21 08:00AM  
May-13-21 04:02PM  
08:00AM  
Apr-27-21 08:00AM  
Mar-31-21 07:44AM  
07:37AM  
Mar-30-21 04:01PM  
Mar-24-21 04:05PM  
Mar-15-21 08:00AM  
Mar-03-21 10:02AM  
Mar-02-21 08:00AM  
Feb-18-21 08:00AM  
Feb-12-21 03:00PM  
Feb-09-21 08:00AM  
Feb-07-21 03:16AM  
Feb-05-21 05:36PM  
Feb-04-21 08:00AM  
Jan-22-21 08:00AM  
Jan-05-21 08:00AM  
Dec-29-20 11:27AM  
Dec-21-20 08:00AM  
Dec-07-20 08:00AM  
Nov-30-20 09:30PM  
08:00AM  
Nov-26-20 10:24AM  
Nov-25-20 08:46AM  
08:00AM  
Nov-10-20 04:05PM  
08:35AM  
Nov-06-20 08:35AM  
Nov-04-20 08:35AM  
Oct-29-20 04:13PM  
Oct-13-20 11:30AM  
Sep-17-20 04:07PM  
Sep-15-20 08:07AM  
Sep-03-20 04:07PM  
Aug-18-20 04:05PM  
Aug-13-20 09:42PM  
04:02PM  
Aug-12-20 08:37AM  
Aug-11-20 08:20AM  
08:00AM  
07:51AM  
Aug-10-20 04:07PM  
Jul-30-20 04:07PM  
Jul-14-20 11:47AM  
10:54AM  
Jul-13-20 07:33AM  
03:30AM  
Jun-03-20 09:00AM  
May-21-20 04:07PM  
May-13-20 04:07PM  
May-07-20 04:07PM  
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Keyes Jason AChief Financial OfficerApr 04Sale3.188,00025,44089,720Apr 05 05:40 PM
Keyes Jason AChief Financial OfficerDec 01Sale5.085,00025,40297,720Dec 03 01:57 PM
Zedelmayer ChristineSr. Vice President and COONov 16Option Exercise2.4523,33457,168109,759Nov 17 03:27 PM
Zedelmayer ChristineSr. Vice President and COONov 16Sale5.4911,43462,71594,759Nov 17 03:27 PM
Connelly StephenChief Scientific OfficerOct 06Option Exercise4.168,09233,626998,625Oct 07 09:02 PM
Connelly StephenChief Scientific OfficerOct 06Sale7.018,09256,706993,000Oct 07 09:02 PM
Keyes Jason AChief Financial OfficerSep 27Sale6.748,00053,924102,720Sep 29 01:02 PM
Keyes Jason AChief Financial OfficerJul 27Sale5.725,00028,585110,720Jul 28 11:55 AM
Connelly StephenChief Scientific OfficerJun 08Option Exercise4.7510,49549,8511,003,495Jun 09 06:03 AM
Connelly StephenChief Scientific OfficerJun 08Sale7.1810,49575,315993,000Jun 09 06:03 AM
Connelly StephenChief Scientific OfficerJun 07Option Exercise4.0122,39089,7971,006,900Jun 09 06:03 AM
Connelly StephenChief Scientific OfficerJun 07Sale7.1222,390159,409993,000Jun 09 06:03 AM
Connelly StephenChief Scientific OfficerJun 04Option Exercise3.8113,53951,6181,000,030Jun 09 06:03 AM
Connelly StephenChief Scientific OfficerJun 04Sale7.0113,53994,846993,000Jun 09 06:03 AM
Keyes Jason AChief Financial OfficerMay 26Sale6.505,00032,484115,720May 28 06:20 PM